fluzoparib Search Results


fluzoparib  (MedChemExpress)
93
MedChemExpress fluzoparib
Fluzoparib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluzoparib/custom%40hy-114778%4042439473?v=MedChemExpress
Average 93 stars, based on 1 article reviews
fluzoparib - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
olaparib  (Selleck Chemicals)
91
Selleck Chemicals olaparib
<t>Olaparib</t> associates with PARP1 in a concentration-dependent manner. (A–C) Representative graphs showing the changes in the FP signal over time following the addition of NAD + to a complex of PARP1, p18mer*, and olaparib (10 nM in A, 20 nM in B, and 40 nM in C) at varying delay times (1.5–150 s) following addition of olaparib. Each line in the graph corresponds to the indicated delay time after addition of olaparib. The replots (measured linear rates vs delay times) are shown on the right for each graph of the primary data and reveal the apparent rate of association ( k obs ) under the experimental conditions. (D) The graph shown is a re-replot of the k obs derived from the replots shown in the insets of (A–C) vs the concentration of olaparib. The linear dependence of these k obs demonstrates a simple one-step mechanism of association. The other PARPi that were subjected to this concentration-dependent <t>experiment</t> <t>(fluzoparib,</t> talazoparib, and saruparib) are shown in Figures S1–S3 .
Olaparib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluzoparib/pmc10433523-40-2-16?v=Selleck+Chemicals
Average 91 stars, based on 1 article reviews
olaparib - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier
fluzoparib, bgb-290  (MedKoo Inc)
90
MedKoo Inc fluzoparib, bgb-290
<t>Olaparib</t> associates with PARP1 in a concentration-dependent manner. (A–C) Representative graphs showing the changes in the FP signal over time following the addition of NAD + to a complex of PARP1, p18mer*, and olaparib (10 nM in A, 20 nM in B, and 40 nM in C) at varying delay times (1.5–150 s) following addition of olaparib. Each line in the graph corresponds to the indicated delay time after addition of olaparib. The replots (measured linear rates vs delay times) are shown on the right for each graph of the primary data and reveal the apparent rate of association ( k obs ) under the experimental conditions. (D) The graph shown is a re-replot of the k obs derived from the replots shown in the insets of (A–C) vs the concentration of olaparib. The linear dependence of these k obs demonstrates a simple one-step mechanism of association. The other PARPi that were subjected to this concentration-dependent <t>experiment</t> <t>(fluzoparib,</t> talazoparib, and saruparib) are shown in Figures S1–S3 .
Fluzoparib, Bgb 290, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluzoparib/us11596637-121-109-113?v=MedKoo+Inc
Average 90 stars, based on 1 article reviews
fluzoparib, bgb-290 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
fluzoparib  (Jiangsu Hengrui Medicine)
86
Jiangsu Hengrui Medicine fluzoparib
<t>Olaparib</t> associates with PARP1 in a concentration-dependent manner. (A–C) Representative graphs showing the changes in the FP signal over time following the addition of NAD + to a complex of PARP1, p18mer*, and olaparib (10 nM in A, 20 nM in B, and 40 nM in C) at varying delay times (1.5–150 s) following addition of olaparib. Each line in the graph corresponds to the indicated delay time after addition of olaparib. The replots (measured linear rates vs delay times) are shown on the right for each graph of the primary data and reveal the apparent rate of association ( k obs ) under the experimental conditions. (D) The graph shown is a re-replot of the k obs derived from the replots shown in the insets of (A–C) vs the concentration of olaparib. The linear dependence of these k obs demonstrates a simple one-step mechanism of association. The other PARPi that were subjected to this concentration-dependent <t>experiment</t> <t>(fluzoparib,</t> talazoparib, and saruparib) are shown in Figures S1–S3 .
Fluzoparib, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluzoparib/pmc13034738-53-6-8?v=Jiangsu+Hengrui+Medicine
Average 86 stars, based on 1 article reviews
fluzoparib - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
fluzoparib  (Biosynth Carbosynth)
N/A
   Buy from Supplier
fluzoparib  (MuseChem Chemicals)
N/A
Fluzoparib (Cat No.: I006894) is an orally active, potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, particularly PARP1 and PARP2. By blocking DNA repair through the base excision repair pathway, fluzoparib enhances DNA damage and
   Buy from Supplier
fluzoparib  (TargetMol)
N/A
   Buy from Supplier
fluzoparib (shr-3162)  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


Olaparib associates with PARP1 in a concentration-dependent manner. (A–C) Representative graphs showing the changes in the FP signal over time following the addition of NAD + to a complex of PARP1, p18mer*, and olaparib (10 nM in A, 20 nM in B, and 40 nM in C) at varying delay times (1.5–150 s) following addition of olaparib. Each line in the graph corresponds to the indicated delay time after addition of olaparib. The replots (measured linear rates vs delay times) are shown on the right for each graph of the primary data and reveal the apparent rate of association ( k obs ) under the experimental conditions. (D) The graph shown is a re-replot of the k obs derived from the replots shown in the insets of (A–C) vs the concentration of olaparib. The linear dependence of these k obs demonstrates a simple one-step mechanism of association. The other PARPi that were subjected to this concentration-dependent experiment (fluzoparib, talazoparib, and saruparib) are shown in Figures S1–S3 .

Journal: Biochemistry

Article Title: Slow Dissociation from the PARP1–HPF1 Complex Drives Inhibitor Potency

doi: 10.1021/acs.biochem.3c00243

Figure Lengend Snippet: Olaparib associates with PARP1 in a concentration-dependent manner. (A–C) Representative graphs showing the changes in the FP signal over time following the addition of NAD + to a complex of PARP1, p18mer*, and olaparib (10 nM in A, 20 nM in B, and 40 nM in C) at varying delay times (1.5–150 s) following addition of olaparib. Each line in the graph corresponds to the indicated delay time after addition of olaparib. The replots (measured linear rates vs delay times) are shown on the right for each graph of the primary data and reveal the apparent rate of association ( k obs ) under the experimental conditions. (D) The graph shown is a re-replot of the k obs derived from the replots shown in the insets of (A–C) vs the concentration of olaparib. The linear dependence of these k obs demonstrates a simple one-step mechanism of association. The other PARPi that were subjected to this concentration-dependent experiment (fluzoparib, talazoparib, and saruparib) are shown in Figures S1–S3 .

Article Snippet: Veliparib (S1004), olaparib (S1060), fluzoparib (S9712), rucaparib (S1098), niraparib (S2741), and talazoparib (S7048) were purchased from Selleck.

Techniques: Concentration Assay, Derivative Assay

Measured Rates of Association ( k on ) for PARPi to PARP1 ± HPF1 <xref ref-type= a " width="100%" height="100%">

Journal: Biochemistry

Article Title: Slow Dissociation from the PARP1–HPF1 Complex Drives Inhibitor Potency

doi: 10.1021/acs.biochem.3c00243

Figure Lengend Snippet: Measured Rates of Association ( k on ) for PARPi to PARP1 ± HPF1 a

Article Snippet: Veliparib (S1004), olaparib (S1060), fluzoparib (S9712), rucaparib (S1098), niraparib (S2741), and talazoparib (S7048) were purchased from Selleck.

Techniques: